WO2001000814A2 - Hetero-associating coiled-coil peptides and screenign method therefor - Google Patents
Hetero-associating coiled-coil peptides and screenign method therefor Download PDFInfo
- Publication number
- WO2001000814A2 WO2001000814A2 PCT/EP2000/005922 EP0005922W WO0100814A2 WO 2001000814 A2 WO2001000814 A2 WO 2001000814A2 EP 0005922 W EP0005922 W EP 0005922W WO 0100814 A2 WO0100814 A2 WO 0100814A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- poly
- peptide
- hetero
- associating
- peptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 184
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 82
- 238000000034 method Methods 0.000 title claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 81
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 80
- 239000013598 vector Substances 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 55
- 239000012634 fragment Substances 0.000 claims description 40
- 102100024746 Dihydrofolate reductase Human genes 0.000 claims description 37
- 108020001096 dihydrofolate reductase Proteins 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 28
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 230000027455 binding Effects 0.000 claims description 8
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims description 8
- 229960001082 trimethoprim Drugs 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 150000007523 nucleic acids Chemical group 0.000 claims description 7
- 230000014509 gene expression Effects 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 241001529936 Murinae Species 0.000 claims description 5
- 108091023040 Transcription factor Proteins 0.000 claims description 3
- 102000040945 Transcription factor Human genes 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 108090001090 Lectins Proteins 0.000 claims description 2
- 102000004856 Lectins Human genes 0.000 claims description 2
- 108090001030 Lipoproteins Proteins 0.000 claims description 2
- 102000004895 Lipoproteins Human genes 0.000 claims description 2
- 230000000975 bioactive effect Effects 0.000 claims description 2
- 210000004900 c-terminal fragment Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 239000002523 lectin Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 239000000813 peptide hormone Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- 238000005734 heterodimerization reaction Methods 0.000 abstract description 7
- 108020001507 fusion proteins Proteins 0.000 abstract description 6
- 102000037865 fusion proteins Human genes 0.000 abstract description 6
- 108020004414 DNA Proteins 0.000 description 22
- 230000003993 interaction Effects 0.000 description 22
- 102220499981 Target of EGR1 protein 1_I114A_mutation Human genes 0.000 description 16
- 239000000539 dimer Substances 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 239000000833 heterodimer Substances 0.000 description 12
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 11
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 11
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 11
- 238000009826 distribution Methods 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 10
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000004925 denaturation Methods 0.000 description 9
- 230000036425 denaturation Effects 0.000 description 9
- 230000002209 hydrophobic effect Effects 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 239000004202 carbamide Substances 0.000 description 6
- 238000002983 circular dichroism Methods 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 239000000710 homodimer Substances 0.000 description 6
- 238000004062 sedimentation Methods 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000006384 oligomerization reaction Methods 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102100023132 Transcription factor Jun Human genes 0.000 description 4
- KRNYOVHEKOBTEF-YUMQZZPRSA-N Val-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O KRNYOVHEKOBTEF-YUMQZZPRSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 239000006152 selective media Substances 0.000 description 4
- 102100027584 Protein c-Fos Human genes 0.000 description 3
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 3
- KFZOFUZZBLYWJI-UHFFFAOYSA-N acetic acid;3-aminopropanoic acid Chemical compound CC(O)=O.NCCC(O)=O KFZOFUZZBLYWJI-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000013378 biophysical characterization Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000037433 frameshift Effects 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000002898 library design Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- KWBQPGIYEZKDEG-FSPLSTOPSA-N Asn-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O KWBQPGIYEZKDEG-FSPLSTOPSA-N 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101100288418 Staphylococcus xylosus lacP gene Proteins 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001142 circular dichroism spectrum Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000003398 denaturant Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000000368 destabilizing effect Effects 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 108010021889 valylvaline Proteins 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 102000015936 AP-1 transcription factor Human genes 0.000 description 1
- 108050004195 AP-1 transcription factor Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 244000292604 Salvia columbariae Species 0.000 description 1
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
- 235000001498 Salvia hispanica Nutrition 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- WITCOKQIPFWQQD-FSPLSTOPSA-N Val-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O WITCOKQIPFWQQD-FSPLSTOPSA-N 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000014167 chia Nutrition 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 238000011102 hetero oligomerization reaction Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000003157 protein complementation Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000010512 thermal transition Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to methods for the identification of novel hetero- associating coiled-coil peptides and uses of these peptides for hetero-dimerization of fusion proteins. It furthermore relates to vectors, host cells useful for the production of these novel hetero-association peptides and (poly)peptides/proteins comprising these peptides.
- proteins which combine two or more functions are prepared either as fusion proteins or through chemical conjugation of the component functional domains. Both of these approaches suffer from disadvantages. Genetic "single chain" fusions suffer the disadvantages that (i) only a few (two to three) proteins can be fused (1 ), (ii) mutual interference between the component domains may hinder folding, and (iii) the size of the fusion protein may make it difficult to prepare.
- the alternative, chemical cross-linking in vitro following purification of independently expressed proteins is difficult to control and invariably leads to undefined products and to a severe loss in yield of functional material.
- a third approach takes advantage of using genetic fusions of functional to association domains which lead to a self-association on co-expression in appropriate host cells.
- the domains must have a tendency to form hetero-multimers.
- a natural protein or protein domain was dissected and fused to protein partners to achieve hetero- association of the fusion proteins via the reconstitution of the native-like structure of the dissected protein or protein domain (WO 96/13583).
- hetero-association can be achieved with complementary helices such as the hetero-dimerizing Jun and Fos zippers of the AP-1 transcription factor (2) or other helical coiled-coil structures which are involved in the oligomerization of a wide variety of proteins. Because of their small size and structural regularity, they have also been used as artificial domains to mediate oligomerization of various proteins (3, 4).
- complementary helices such as the hetero-dimerizing Jun and Fos zippers of the AP-1 transcription factor (2) or other helical coiled-coil structures which are involved in the oligomerization of a wide variety of proteins. Because of their small size and structural regularity, they have also been used as artificial domains to mediate oligomerization of various proteins (3, 4).
- the association of two separately expressed scFv antibody fragments by C-terminally fused amphipathic helices in vivo provides homo-dimers of antibody fragments in E. coli (WO93/15210; 5, 6).
- Fig. 1A, (7, 8) They contain a characteristic heptad repeat (abcdefg) n with a distinct pattern of hydrophobic and hydrophilic residues (Fig. 1A, (7, 8)).
- the positions a and d, which form the hydrophobic interface between the helices, are usually aliphatic and a have profound effect on the oligomerization state (9, 10).
- the positions b, c, e, g, and f are solvent-exposed and usually polar.
- the positions e and g, which flank the hydrophobic core, can make interhelical interactions between g, and e' l+5 residues, and thereby mediate heterospecific pairing (11-14).
- association domains based on hetero-associating helices is their pseudo-symmetry and their similar periodicity of hydrophobic and hydrophilic residues.
- This structural similarity resulted in a strong tendency to form homo-dimers and thus to lower significantly the yield of hetero-dimers (2, 16).
- the formation of Jun/Fos hetero-dimers is kinetically disfavoured and requires a temperature-dependent unfolding of the kinetically favoured homo-dimers, especially Jun/Jun homo-dimers (WO 93/15210; 2, 16).
- hetero-association domains based on amphipathic helices have so far not resulted in practical advantages compared to conventional chemical coupling. Further, it is not currently possible to predict sequences of coiled coil-forming peptides that will simultaneously have high stability and heterospecificity as well as advantageous in-vivo properties, such as resistance to proteases. This is crucial to practical applications of optimal interacting heterodimers for in vivo studies of protein oligomerization, e.g. the design of bispecific miniantibodies (17).
- the technical problem underlying the present invention is to provide association domains based on helical coiled-coil structures which lead to hetero-association.
- the solution to the above technical problem is achieved by the embodiments characterized in the claims.
- the present invention provides a method which allows to identify hetero-associating (poly)peptides.
- the technical approach i.e. the design of an appropriate coiled-coil library and screening by using a library-vs-library approach is neither provided nor suggested by the prior art.
- the present invention relates to a method for the identification of hetero- associating (poly)peptides comprising the steps of:
- (poly)peptide relates to molecules consisting of one or more chains of multiple, i. e. two or more, amino acids linked via peptide bonds.
- protein refers to (poly)peptides where at least part of the (poly)peptide has or is able to acquire a defined three-dimensional arrangement by forming secondary, tertiary, or quaternary structures within and/or between its (poly)peptide chain(s).
- This definition comprises proteins such as naturally occurring or at least partially artificial proteins, as well as fragments or domains of whole proteins, as long as these fragments or domains have a defined three-dimensional arrangement as described above.
- the commonly known one-letter code for amino acid residues is used.
- screenable or selectable property refers to a property which is generated in the event of a successful interaction taking place during screening or selection.
- Examples for screenable selectable properties include, but are not limited to, binding to a target or presentation of a target for ligand-binding, enzymatic activity, transactivation of transcription of a reporter gene such as beta-galactosidase, alkaline phosphatase or nutritional markers such as his3 and leu, or resistance genes giving resistance to an antibiotic such as ampicillin, chloramphenicol, kanamycin, zeocin, neomycin, tetracycline or streptomycin.
- the selectable or screenable property can be restoration of phage infectivity to a filamentous phage rendered non-infectious by deletion of the N-terminal domain(s) of the genelll protein (U.S. Patent No. 5,514,548).
- the invention relates to a method wherein said libraries A and B are provided by providing libraries of nucleic acid sequences encoding said (poly)peptides/proteins, followed by causing or allowing the expression of said libraries of (poly)peptides/proteins.
- said common medium are host cells, each cell harbouring nucleic acid sequences encoding a (poly)peptide/protein of each of said libraries A and B.
- said (poly)peptides/proteins of said libraries A and B further comprise either a N- or a C-terminal fragment of the murine DHFR enzyme, and wherein said screenable or selectable property is insensitivity of the host cell to t methoprim by reconstitution of the DHFR enzyme on hetero-association of (poly)peptides A m and B ⁇ .
- the DHFR assay has been published (WO 98/34120; 19) and is further exemplified in the examples.
- the present invention relates to a hetero-associating
- WINZIPA11 VAQLRERVKTLRARNYELQSKVQRLKERVAQL Furthermore, the present invention relates to a hetero-associating (poly)peptide B n taken from the list of:
- WINZIPB1 VDELQAEVDQLQDENYALKTKVAQLRKKVEKL
- WINZIPB2 VDELKAEVDQLQDQNYALRTKVAQLRKEVEKL
- WINZIPB3 VDELEAEVDQLKDQNYALKTKVAQLQKQVEKL
- WINZIPB4 VDELRAKVDQLQDENYALETEVAQLQKRVEKL
- WINZIPB6 VDELKAKVDQLKDKNYALRTKVAQLRKKVEKL
- WINZIPB7 VDELRAQVDQLQDKNYALRTRVAQLKKRVEKL
- WINZIPB8 VDELQAEVDQLQDQNYALRTQVAQLKKKVEKL
- WINZIPB10 VDELQAKVDQLKDENYALQTKVAQLQKRVEKL
- hetero-associating (poly)peptide for the identification of optimized hetero-associating (poly)peptides in a method according to the present invention, wherein one of the hetero-associating peptide WinZipA m as listed hereinabove is used instead of library A of (poly)peptides/proteins comprising (poly)peptides A m in step (a) above, or wherein a hetero-associating peptide WinZip B n as listed hereinabove is used instead of library B of (poly)peptides/proteins comprising (poly)peptides B n in step (b) avove.
- the present invention relates to an optimized hetero-associating (poly)peptide obtainable by the method of the present invention.
- the present invention relates to a pair of hetero- associating (poly)peptides taken from the list of: WinZipAI and WinZipBI WinZipA2 and WinZipBI WinZipAI and WinZip B2 WinZipA3 and WinZip B3 WinZipA4 and WinZip B4 WinZipA ⁇ and WinZip B5 WinZipA6 and WinZip B6 WinZipA7 and WinZip B7 WinZipA ⁇ and WinZip B8 WinZipA9 and WinZip B9 WinZipAI 0 and WinZip B10 WinZipA11 and WinZip B11
- the invention relates to a (poly)peptide/protein comprising one of the hetero-associating (poly)peptides, or an optimized hetero- associating (poly)peptide of the present invention, and a further (poly)peptide/protein.
- (poly)peptide/protein comprising one of the hetero-associating (poly)peptides, or an optimized hetero-associating (poly)peptide of the present invention, and a further (poly)peptide/protein” refers to all constructs which comprise one of the hetero-association peptides according to the present invention and additional moieties.
- This comprises (poly)peptides/proteins which are expressed from a contiguous nucleic acid coding sequence. Additionally, this comprises constructs where the individual components are expressed from different nucleic acid coding sequences, or where the components are produced by peptide synthesis, and where the separate components are linked by the formation of disulfide bonds or by chemical conjugation.
- Still further preferred is a (poly)peptide/protein wherein said further (poly)peptide/protein is an enzyme, a toxin, a cytokine, a metal binding domain, a transcription factor, a member of the immunoglobulin superfamily, a bioactive peptide of 5 to 15 amino acid residues, a peptide hormone, a growth factor, a lectin, a lipoprotein, a peptide which is able to bind to an independent binding entity, or a functional fragment of any said further (poly)peptide/protein.
- said further (poly)peptide/protein is an enzyme, a toxin, a cytokine, a metal binding domain, a transcription factor, a member of the immunoglobulin superfamily, a bioactive peptide of 5 to 15 amino acid residues, a peptide hormone, a growth factor, a lectin, a lipoprotein, a peptide which is able to bind to an independent binding entity, or
- the present invention relates to a hetero-associated (poly)peptide/protein comprising at least two (poly)peptide/proteins of the present invention, associated by hetero-association of a hetero-associating (poly)peptide A m and a hetero-associating (poly)peptide B n .
- hetero-associated (poly)peptide/protein refers to all bispecific and/or bivalent complexes formed by taking advantage of the hetero-associating peptides according to the present invention.
- These include, for example, constructs where said "further (poly)peptides/proteins" are two antibody fragments directed against different specificities.
- Such bispecific constructs can be used to increase selectivity of antibody- based approaches in therapy of diseases where the target cells exhibit a pattern of two cell-surface markers distinct from that of non-target cells which may present one of the two markers.
- one of the antibody specificities may be directed to a target cells, whereas the second may be used to target a drug carrier moiety selectively to the target.
- antibody fragments as targeting vehicles may be combined with (poly)peptides/proteins which serve as effector domains, such as enzymes or signalling molecules.
- a DNA sequence encoding a hetero-associating (poly)peptide taken from the list of WINZIPAI to WINZIPA11 and WinZipBI to WinZipB11 , or encoding an optimized hetero-associating (poly)peptide or a (poly)peptide/protein of the present invention.
- a DNA sequence encoding a hetero-associating (poly)peptide wherein said DNA sequence hybridizes under stringent conditions to a DNA sequence encoding a hetero-associating (poly)peptide taken from the list of WinZipAI to WinZipA11 and WinZipBI to WinZipB11.
- hybridizes under stringent conditions is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.
- the conditions are such that at least sequences at least 65%, more preferably at least 70%, and even more preferably at least 75% homologous to each other typically remain hybridized to each other.
- stringent hybridization conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, New York. (1989), 6.3.1 -6.3.6.
- a preferred, non-limiting example of stringent hybridization conditions is hybridization in 6 x sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 x SSC, 0.1% SDS at 50°-65°C.
- the invention relates to a vector comprising a DNA sequence according to the invention.
- the invention relates to a vector comprising DNA sequences encoding at least two (poly)peptide/, comprising at least a hetero-associating (poly)peptide A m and a hetero-associating (poly)peptide B n .
- the invention relates to a host cell containing at least one vector of the present invention.
- the host cell is a mammalian, preferably human cell, a yeast cell, an insect cell, a plant cell, or a bacterial, preferably E.coli cell.
- the invention relates to a method for the production of a hetero-associating (poly)peptide, an optimized hetero-associating (poly), a (poly)peptide/protein, or a hetero-associated (poly)peptide/protein of the present invention, which comprises culturing the host cell of the present invention in a suitable medium, and recovering said (poly)peptide or said (poly)peptide/protein produced by said host cell.
- the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising the hetero-associated (poly)peptide/protein or the present invention.
- Still further preferred is a diagnostic composition comprising the hetero-associated (poly)peptide/protein of the present invention.
- kits containing at least one of a hetero-associating (poly)peptide, an optimized hetero-associating (poly)peptide, or a
- polypeptide/protein of claims or a hetero-associated (poly)peptide/protein of the present invention; or a vector of claims according to the invention.
- Figure 1 (A) Schematic representation of a parallel dimeric coiled coil. Hatched bars indicate the possible interhelical interactions between e and g positions. (B) Schematic representation of the protein complementation assay as described in the Examples. Introduction of a mutation at the DHFR interface (1114A) was used to increase selection stringency (19). (C) Overview of the library design depicted as a helical wheel plot from the N- to the C-terminus (inside to outside. The randomized positions are indexed ( * : equimolar mixture of Q, E, K, R, x: equimolar mixture of N, V). The selected residues from the predominant pair, WinZip-A1 B1 (clone #1 , Fig.
- FIG. 2 (A) DNA constructs code for fusions between library proteins (shown as a- helical leucine zippers) and either fragment of murine DHFR (mDHFR). Fusions were created using either the wild-type or the mutant mDHFR fragment 2 (Ile114Ala), yielding LibA-DHFR[1] and LibB-DHFR[ 2] or LibB-DHFR[2:l114A], respectively.
- mDHFR can fold from the individual fragments resulting in active enzyme and bacterial growth. Both mDHFR fragments must be present, and dimerization of the fused proteins is essential, in order for cell propagation to be possible. No growth is observed if any of these conditions is not fulfilled (19) .
- the surviving colonies are the result of "single-step selection” and can be directly analyzed by DNA sequencing.
- C "Competition selection” is undertaken by pooling colonies from (B) in selective, liquid culture (passage 0 or P0), propagating the cells and diluting into fresh selective medium for further passages. An aliquot can be plated and the resulting colonies analyzed by DNA sequencing.
- FIG. 3 Competition selection and chain shuffling.
- B Quantitation of the colony sizes from (A). For comparative purposes, quantitation of colony sizes of cells transformed with DNA of WinZip-A1 B1 (but not passaged in liquid culture) is shown.
- C Quantitation of the colony sizes from passages of the chain shuffling experiment: WinZip-B1-DHFR[2:l114A] + LibA-DHFR[1]. In (B) and (C) the numbers of colonies were normalized such that passages could be directly compared.
- Figure 4 (A) Schematic representation of a leucine zipper pair visualized from the N- terminus illustrating e/g-interactions and the hydrophobic core formed by the a- and d- positions. (B) Distribution of residues at the semi-randomized positions throughout selection. The number of zipper pairs sequenced is given in parentheses, save “Before selection” where the theoretical distribution is reported. Each pair carries one core a-pair and 6 e/g-pairs. Neutral e/g-pairs have one or both residues as Gin. In "Competition (I114A)" only clones from P6 to P12 (not from earlier passages) were considered for analysis.
- FIG. 5 Efficiency of competition in a model selection. The selection was set up by mixing known numbers of cells expressing either GCN4-DHFR[1]/GCN4-DHFR[2:I114A] fusions or one of 7 LibA-DHFR[1]/LibB-DHFR[2:M 14A] pairs previously selected by single-step selection. The starting ratio was 2.9 x 10 4 : 1 (GCN4 to Lib). Competition selection was undertaken as described in Figure 2C, and in the Examples. The appearance of the library pairs in the pool was monitored by restriction analysis.
- a Piull fragment (1138 bp) is unique to the LibB sequence of the LibB-DHFR[2] plasmid, while another (762 bp) is from pRep4 (repressor plasmid) and remains approximately constant.
- the bands were quantitated using the NIH Image gel analysis function to calculate the ratio of LibB/pRep4 (indicated below each lane).
- Figure 7 Positional distribution of amino acids at each e- and g-position in sequences obtained from the highest stringency selection. The statistically expected random occurrence of each amino acid at each position was subtracted from the relative occurrence observed in the selection (Q left (black), E middle (grey), K/R right (black)).
- Figure 8 (A) Determination of the molecular weight of WinZip-A1 B1 by sedimentation equilibrium. The upper panel shows the residuals between measured data obtained at 10 ⁇ M peptide concentration at 25°C and data fitted as monomer (top), dimer (middle), or trimer (bottom). The lower panel shows the residuals for a dimeric fit to the data set obtained at 150 ⁇ M peptide concentration, 10°C.
- Figure 9 CD-measurements of the synthesized peptides of WinZip-A1 B1.
- A Temperature dependence of [ ⁇ ] 222 for WinZip-A1 B1 ( ⁇ ), WinZip-A1 (A), WinZip-B1 (T), and the calculated average of both homodimers ( ).
- B Dependence of T m and ⁇ T m
- Figure 11 (A) Sequences of (poly)peptides WinZipAI to WinZipA11
- CD circular dichroism
- mDHFR murine dihydrofolate reductase
- WinZip dominant zipper pairs obtained from competition selection; WinZip-A1 B1 original pair selected, comprising peptide A1 from libraryA and peptide B1 from libraryB WinZip-A1 B2 and WinZip-A2B1 : optimized pairs comprising the original partner A1 or B1 and the new partner B2 or A2, respectively.
- Example 1 Selection of hetero-association peptides (see WO 98/34120, Example 7)
- DHFR murine enzyme dihydrofolate reductase
- the DNA constructs encoding the ⁇ /-terminal (1 -107) and C-terminal (108-186) mDHFR fragments have been previously described (19).
- the vectors are variants of plasmids Z- F[1 ,2], encoding the N-terminal DHFR fragment, and Z-F[3] or Z-F[3:I114A], respectively, encoding the C terminal DHFR fragment with or without the 1114A mutation (19), Briefly, each fragment was amplified by PCR with appropriate unique flanking restriction sites and subcloned into a bacterial expression vector (pQE-32 from Qiagen).
- Each plasmid encodes an N-terminal hexahistidine tag, followed by a designed flexible linker and the appropriate DHFR fragment. Unique restriction sites between the hexahistidine tag and the flexible linker allow subcloning of the desired library.
- helix length of 4.5 heptads as good compromise between stability and size.
- positions a, d we chose the residues of the parallel, homodimeric leucine zipper GCN4 (Val at a, Leu at d).
- GCN4 Val at a, Leu at d.
- a single a-position in the middle of each helix is often occupied by a polar residue, most often an Asn, which forms a hydrogen bond inside the hydrophobic core (22, 23).
- Replacement of this Asn pair by a non-polar one increases the stability significantly, but leads to helices packing in different registers and orientations, as well as forming higher order oligomers (24-26).
- the solvent-accessible residues at the e- and g-positions can form interhelical salt bridges or hydrogen bonds which can contribute to stability and heteromeric specificity (13, 14, 28, 29).
- Thnucleotide codons (27) were used to code for randomized positions, all other positions were made with mononucleotides.
- GTGGCGCAACTG and prA-rev GGACTAGTACCTTCGCTAGCAAGCTGGGCAAC or prB-fwd: GGAGTACTGGCATGCAGTCGACCTCCGTTGACGAACTG and prB-rev:
- LibraryA and B were both digested with Sail and Nhel, gel purified and ligated to the appropriate vector (Fig 2) yielding the plasmids LibA-DHFR[1], LibB-DHFR[2], LibB- DHFR[2:I114A] (Fig. 2A). After subcloning, the resulting linker between either library and DHFR fragment was: A(SGTS) 2 STSSGI for LibA and SEA(SGTS) 2 STS for LibB. To achieve maximal library representation, the ligation mixes were individually electroporated into XL1 -Blue cells and selected with ampicillin on rich medium (LB). A 2- to 7-fold over-representation of each library was obtained.
- the resulting colonies were pooled and the plasmid DNA purified such that supercoiled plasmid DNA was obtained for cotransformation.
- the supercoiled DNA was cotransformed in BL21 cells yielding about 4x10 6 double-transformants.
- the occurrence of double transformation was calculated as the number of colonies growing under selective pressure with trimethoprim (described below) divided by the number growing in the absence, when cotransformed with equal amounts of each DNA of a given, pre-selected pair.
- Selective pressure for DHFR was maintained throughout all steps by inhibiting the bacterial DHFR with trimethoprim (1 mg/ml) in minimal medium. Ampicillin and kanamycin (100 mg/ml and 50 mg/ml, respectively) were also included in all steps to retain the library plasmids and the lacP repressor-encoding plasmid (pRep4), respectively. Expression of the proteins was induced with 1 mM IPTG. When selecting on solid medium, growth was allowed for 45 hrs at 37°C.
- the number of viable cells in the starter cultures was quantitated as follows.
- the appropriate clones were propagated in liquid media under selective conditions and dilute aliquots were frozen at -80°C with 15% glycerol.
- One aliquot for each clone was thawed and plated under selective conditions, and the colonies counted after 45 hrs.
- the volume of cells to use for P0 was then calculated, such that each clone should be over- represented by a factor of at least 2000.
- Colony sizes (in Fig. 3) were evaluated using the NIH Image Particle Analysis Facility. When selecting in liquid medium, the starting O.D. (600 nm) was either 0.0005 or 0.0001.
- a single-step selection was undertaken, using the wild-type mDHFR fragments, by cotransforming the libraries LibA-DHFR[ 1] and LibB-DHFR[2] and plating on selective media (Fig. 2B).
- This strategy applies only a low stringency of selection to the potential pairs, thus many library combinations were expected to be selected.
- Approximately 1.7% of the resulting ampicillin-resistant cells were doubly transformed, harboring (at least) one plasmid from each library when using 5 ng of each DNA, or 8% were doubly transformed when using 20 ng of each DNA, as seen from control transformations (calculated as described above).
- the peptide linkers that connect the library sequences to the DHFR fragments must be sufficiently flexible to allow DHFR to fold from its fragments, but not so long that any C-terminal to ⁇ /-terminal orientation of the final folded leucine zipper would be allowed.
- parallel in-register heterodimerization of the library peptides is the only configuration possible.
- Other biases in these sequences were also more pronounced than with the wt DHFR fragments (Fig. 4B).
- an additional increase in opposite-charged e/g-pairs from 31 % to 37% was seen.
- a point-mutation resulted in a single clone (1/25) with a V-T pair at the core a-position.
- the initial cell mixture contained known amounts of viable cells expressing either GCN4- DHFR[1]/GCN4-DHFR[2:I114A] or one of seven LibA-DHFR[1]/LibB- DHFR[2:I114A] pairs previously obtained in a single-step selection of those libraries, mixed at a ratio of 2.9 x 10 4 : 1 (GCN4 : library clones).
- GCN4 library clones
- the library pairs were already visibly enriched (Fig. 5), and after 5 passages the measured ratio between a restriction fragment indicative of the library and a constant fragment from the repressor plasmid had reached its maximium, showing that enrichment was maximal.
- Clones resulting from the three selection strategies with increasing stringencies were analyzed and compared: (i) lowest stringency: 14 clones analyzed, (ii) medium stringency: 25 clones analyzed (see Table 2), (iii) highest stringency: 41 clones analyzed from various passages.
- the last passage (P12) yielded a population dominated by a single pair of coiled-coil sequences, WinZip-A1 B1 , as described above (Fig. 1 C, clone #1 in Fig. 1 D), which was biophysically analyzed (see below).
- the sequences of clones surviving at least up to passage 10 are reported in Figure 1 D.
- Intrahelical electrostatic interactions can influence stability and may even promote selection of apparently repulsive e/g-pairs. Interactions with the helix macrodipole, for example, can modulate stability in coiled coils (37). Indeed, we observed a bias for negatively charged and neutral amino acids in the N-terminal part and positively charged amino acids in the C-terminal part (Fig. 7). This positional preference may at least partially compensate the loss of stability resulting from a repulsive e/g-interaction. In addition, interactions with adjacent residues on the outside of the helix (b- and c positions) may influence the contributions of charges at the e- and g positions (38).
- WinZip-A1 B1 contains the most important features for stability and heterospecificity. Furthermore, the random probability of finding pairs with no repulsive interactions was 1 :40, and with solely attractive interactions was 1 :1.6x10 4 . Thus, our selection covered a representative sequence space and the same-charged interactions in WinZip-A1 B1 are not a result of incomplete library sampling but must have more subtle reasons, including in-vivo factors, which we cannot fully address. Furthermore, in the medium as well as in the highest stringency selection 13 out of 38 pairs sequenced had no repulsive e/g pairs, but none competed successfully against WinZip-A1 B1 in the selection.
- the peptides WinZip-A1 Ac-STTVAQLEEKVKTLRAQNYELKSRVQRLREQVAQLAS- NH2 and WinZip-B1 : Ac-STSVDELQAEVDQLQDENYALKTKVAQLRKKVEKLSE-NH2 were synthesized (Applied Biosystem 431 A) and purified by reversed-phase HPLC. Electrospray mass spectrometry confirmed purity and identity of the peptides with a mass deviation of less than 1 Da. Peptide concentrations were determined by tyrosine absorbance in 6 M GdnHCI (39).
- T m were determined by least-squares curve fitting of the denaturation curves (40), assuming a two-state model.
- ⁇ T m was calculated as T m (WinZip-A1 B1 )- 1 /2[T m (WinZip-A1 )+T m (WinZip-B1 )].
- the helical content was in the range of 90% (WinZip B1) to 100% (WinZip-A1 and WinZip-A1 B1).
- Peptide WinZip-A1 as well as the mixture WinZip-A1 B1 (Fig. 4A) were dimeric at 10°C and 25°C over a concentration range from 10 ⁇ M to 150 ⁇ M as determined by equilibrium sedimentation.
- WinZip-B1 was partially unfolded as seen both by CD (Fig. 8C at 0 M urea) and equilibrium sedimentation.
- Equilibrium sedimentation experiments were performed using a Beckman XL-A Ultracentrifuge. Absorbance was monitored at 220 and 275 nm at peptide concentrations of 10, 50 and 150 ⁇ M in 10 mM K 2 HP0 4 /KH 2 P0 4 , pH 7.0, 100 mM KCI. Partial specific volumes and solvent densities were determined as described (41 ). The data sets were fitted to single molecular masses of monomer, dimer and trimer. Equilibrium sedimentation indicated a mixture of monomers and dimers, with decreasing amount of dimer at increasing temperature.
- the homodimer WinZip-B1 has two same-charged ion pairs, but is significantly less stable than the homodimer WinZip-A1 with four same-charged pairs (Fig. 9). Since the overall helical propensity is comparable for both peptides according to (43), the difference is probably due to intrahelical interactions. LibraryB might be destabilized by its high local concentration of acidic residues at the N-terminus.
- Dissociation constants of the peptides were derived from equilibrium urea denaturations (Fig. 8C).
- the heterodimer WinZip A1 B1 was the most stable species with a K D of approximately 24 nM, while the homodimer WinZip-A1 had a K D of approximately 63 nM.
- the accuracy of the K D determination of WinZip-B1 is lower since it is already partially unfolded without denaturant (see above).
- the K D was estimated to be in the 10 "5 M range. Calculations were confirmed by determining the K values from thermal denaturation curves by a van't Hoff analysis, assuming as a first approximation a constant ⁇ H (40). We found reasonable agreement to the data obtained by urea denaturation with a maximal deviation of K D by a factor of 2.6.
- WinZip-A1 B1 is best compared with other naturally-occurring coiled coils.
- the homodimeric coiled coil of the yeast transcription factor GCN4 has an equal or slightly higher Tm, depending on the length and concentration of the peptides chosen (44, 45).
- the N terminal homodimeric coiled coil of the APC protein has a Tm lower by at least 9°C than WinZip-A1 B1 (46).
- the heterodimeric coiled coil from c-Jun/c-Fos shows comparable Tm and ⁇ T m values (2). However, those data were derived from disulfide-bridged peptides.
- the coiled coil from c-Myc/Max also heterodimerizes to a fairly high extent, but peptides of comparable length have a T m of only 31 °C and a K D of 60 ⁇ M (25°C) (45), whereas our WinZip-A1 B1 has a Tm of 55°C and a K D of approximately 24 nM (20°C). Thus, WinZip-A1 B1 compares successfully with naturally-occurring coiled coils and will therefore be very useful for a variety of in-vivo applications.
- WinZip-A1 B1 was selected from a sample representing 2.0 x 10 6 library-vs-library cotransformants.
- approximately 0.01% of the library-vs-library space was sampled.
- WinZip-A1 B1 as a partially optimized starting point, we combined each of the two WinZip-A1 B1 polypeptides with the opposite library (WinZip-A1 -DHFR[1] + LibB-DHFR[2:H 14A] and WinZip-B1 -DHFR[2:1114A] + LibA-DHFR[1 ]).
- heterospecificity was achieved not only by decreasing the numbers of repulsive e/g-interactions but also by increasing the number of attractive interactions in the heterodimer relative to the homodimers.
- heterospecificity may be a unique feature of this selection system. Not only is active enzyme exclusively formed by parallel heterodimers, but homodimers and higher oligomers are likely to have a negative effect by unproductively wasting fragments and perhaps even harmfully accumulating nonfunctional enzyme. Dimer stability, in turn, is dependent not only on e/g-pair interactions, but also on helical propensity, intrahelical interactions and helix dipole stabilization. Indeed, our analysis revealed that the most successful variants do not simply consist of complementary charges in the e/g-positions, but show a more complicated pattern, presumably fulfilling a variety of naturally conflicting demands on the sequence, whose optimum would have been extremely challenging to predict.
- the selection factor in single-step selection is defined as the number of cotransformed cells plated (considering only the 50% which give combinations with no mutations or frame-shifts), divided by the number of colonies surviving under selective conditions (see Results); average of 2 independent experiments, given with the standard deviation. This value must be calculated at low DNA concentrations ( ⁇ 20 ng of each DNA) since the multiple cotransformations occuring at high DNA concentrations mask the actual selection factor.
- b PI 2 is the 12 th round of serial cell passaging and competitive growth.
- the selection factor in competition selection is defined as the proportion of the dominant pair multiplied by the sequence diversity it was selected from, and is the result of a single experiment.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002377513A CA2377513A1 (en) | 1999-06-25 | 2000-06-26 | Hetero-associating coiled-coil peptides |
EP00943898A EP1194539A2 (en) | 1999-06-25 | 2000-06-26 | Hetero-associating coiled-coil peptides and screening method therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34409699A | 1999-06-25 | 1999-06-25 | |
US09/344,096 | 1999-06-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001000814A2 true WO2001000814A2 (en) | 2001-01-04 |
WO2001000814A3 WO2001000814A3 (en) | 2001-03-22 |
Family
ID=23349034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/005922 WO2001000814A2 (en) | 1999-06-25 | 2000-06-26 | Hetero-associating coiled-coil peptides and screenign method therefor |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1194539A2 (en) |
CA (1) | CA2377513A1 (en) |
WO (1) | WO2001000814A2 (en) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1198586A1 (en) * | 1999-06-26 | 2002-04-24 | Odyssey Pharmaceuticals, Inc. | An in vivo library-versus-library selection of optimized protein-protein interactions |
WO2007110205A3 (en) * | 2006-03-24 | 2008-02-28 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
EP2267024A1 (en) | 2005-06-03 | 2010-12-29 | Ares Trading S.A. | Production of recombinant il-18 binding protein |
WO2011026122A2 (en) | 2009-08-31 | 2011-03-03 | Amplimmune, Inc. | B7-h4 fusion proteins and methods of use thereof |
EP2280066A3 (en) * | 2002-09-12 | 2011-05-11 | Health Protection Agency | Recombinant clostridium neurotoxin fragments |
WO2012001647A2 (en) | 2010-06-30 | 2012-01-05 | Compugen Ltd. | Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders |
WO2012035518A1 (en) | 2010-09-17 | 2012-03-22 | Compugen Ltd. | Compositions and methods for treatment of drug resistant multiple myeloma |
WO2012140627A1 (en) | 2011-04-15 | 2012-10-18 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
WO2013001517A1 (en) | 2011-06-30 | 2013-01-03 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
EP2662383A1 (en) | 2008-08-25 | 2013-11-13 | Amplimmune, Inc. | PD-I antagonists and methods for treating infectious disease |
WO2014008391A1 (en) * | 2012-07-05 | 2014-01-09 | Genentech, Inc. | Expression and secretion system |
US8653073B2 (en) | 2009-08-04 | 2014-02-18 | Les Laboratoires Servier | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them |
WO2014124487A1 (en) | 2013-02-18 | 2014-08-21 | Vegenics Pty Limited | Ligand binding molecules and uses thereof |
WO2014186798A1 (en) | 2013-05-17 | 2014-11-20 | Amplimmune, Inc. | Receptors for b7-h4 |
WO2015190262A1 (en) * | 2014-06-13 | 2015-12-17 | 国立大学法人名古屋大学 | Tagged antibody |
WO2016030888A1 (en) | 2014-08-26 | 2016-03-03 | Compugen Ltd. | Polypeptides and uses thereof as a drug for treatment of autoimmune disorders |
WO2017009712A1 (en) | 2015-07-13 | 2017-01-19 | Compugen Ltd. | Hide1 compositions and methods |
WO2018107125A1 (en) * | 2016-12-09 | 2018-06-14 | Seattle Genetics, Inc. | Bivalent antibodies masked by coiled coils |
US10370455B2 (en) | 2014-12-05 | 2019-08-06 | Immunext, Inc. | Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists |
WO2019217587A1 (en) * | 2018-05-08 | 2019-11-14 | Amgen Inc. | Bispecific antibodies with cleavable c-terminal charge-paired tags |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
US10781254B2 (en) | 2010-03-26 | 2020-09-22 | The Trustees Of Dartmouth College | VISTA regulatory T cell mediator protein, VISTA binding agents and use thereof |
US10899836B2 (en) | 2016-02-12 | 2021-01-26 | Janssen Pharmaceutica Nv | Method of identifying anti-VISTA antibodies |
US10933115B2 (en) | 2012-06-22 | 2021-03-02 | The Trustees Of Dartmouth College | VISTA antagonist and methods of use |
US11009509B2 (en) | 2015-06-24 | 2021-05-18 | Janssen Pharmaceutica Nv | Anti-VISTA antibodies and fragments |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
US11123426B2 (en) | 2014-06-11 | 2021-09-21 | The Trustees Of Dartmouth College | Use of vista agonists and antagonists to suppress or enhance humoral immunity |
US11180557B2 (en) | 2012-06-22 | 2021-11-23 | King's College London | Vista modulators for diagnosis and treatment of cancer |
US11242392B2 (en) | 2013-12-24 | 2022-02-08 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
WO2022227066A1 (en) * | 2021-04-30 | 2022-11-03 | 深圳普瑞金生物药业有限公司 | METHOD FOR SCREENING αβ-TCR HETERODIMER MUTANTS |
US11525000B2 (en) | 2016-04-15 | 2022-12-13 | Immunext, Inc. | Anti-human VISTA antibodies and use thereof |
US11529416B2 (en) | 2012-09-07 | 2022-12-20 | Kings College London | Vista modulators for diagnosis and treatment of cancer |
US11649285B2 (en) | 2016-08-03 | 2023-05-16 | Bio-Techne Corporation | Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy |
US11787857B2 (en) | 2018-02-02 | 2023-10-17 | Bio-Techne Corporation | Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030035798A1 (en) | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998034120A1 (en) * | 1997-01-31 | 1998-08-06 | Universite De Montreal | Protein fragment complementation assays to detect biomolecular interactions |
-
2000
- 2000-06-26 EP EP00943898A patent/EP1194539A2/en not_active Withdrawn
- 2000-06-26 WO PCT/EP2000/005922 patent/WO2001000814A2/en not_active Application Discontinuation
- 2000-06-26 CA CA002377513A patent/CA2377513A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998034120A1 (en) * | 1997-01-31 | 1998-08-06 | Universite De Montreal | Protein fragment complementation assays to detect biomolecular interactions |
Non-Patent Citations (8)
Title |
---|
ARNDT K M ET AL: "In-vivo selection of interacting peptide libraries by selectively-infective phages." FASEB JOURNAL, vol. 11, no. 9, 1997, page A1327 XP002156485 17th International Congress of Biochemistry and Molecular Biology in conjunction with the Annual Meeting of the American Society for Biochemistry and Molecular Biology;San Francisco, California, USA; August 24-29, 1997 ISSN: 0892-6638 * |
ARNDT KATJA M ET AL: "A heterodimeric coiled-coil peptide pair selected in vivo from a designed library-versus-library ensemble." JOURNAL OF MOLECULAR BIOLOGY, vol. 295, no. 3, 21 January 2000 (2000-01-21), pages 627-639, XP002156489 ISSN: 0022-2836 * |
HODGES R S: "DE NOVO DESIGN OF ALPHA-HELICAL PROTEINS: BASIC RESEARCH TO MEDICALAPPLICATIONS" BIOCHEMISTRY AND CELL BIOLOGY. BIOCHIMIE ET BIOLOGIE CELLULAIRE,XX,XX, vol. 74, no. 2, 1996, pages 133-154, XP000605834 ISSN: 0829-8211 cited in the application * |
JOHN MATTHIAS ET AL: "Two pairs of oppositely charged amino acids from Jun and Fos confer heterodimerization to GCN4 leucine zipper." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 23, 1994, pages 16247-16253, XP002156486 ISSN: 0021-9258 cited in the application * |
O'SHEA E K ET AL: "MECHANISM OF SPECIFICITY IN THE FOS-JUN ONCOPROTEIN HETERODIMER" CELL, vol. 68, no. 4, 1992, pages 699-708, XP002156487 ISSN: 0092-8674 cited in the application * |
O'SHEA E K ET AL: "PEPTIDE 'VELCRO*': DESIGN OF A HETERODIMERIC COILED COIL" CURRENT BIOLOGY,GB,CURRENT SCIENCE,, vol. 3, no. 10, 1993, pages 658-667, XP000653001 ISSN: 0960-9822 cited in the application * |
PELLETIER, J.N. ET AL.: "An in vivo library-versus-library selection of optimized protein-protein interactions." NATURE BIOTECHNOLOGY, vol. 17, July 1999 (1999-07), pages 683-90, XP002156488 * |
YU Y ET AL: "INVESTIGATION OF ELECTROSTATIC INTERACTIONS IN TWO-STRANDED COILED-COILS THROUGH RESIDUE SHUFFLING" BIOPHYSICAL CHEMISTRY,AMSTERDAM,NL, vol. 59, 16 April 1996 (1996-04-16), pages 299-314, XP000971324 cited in the application * |
Cited By (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1198586A4 (en) * | 1999-06-26 | 2004-03-24 | Odyssey Pharmaceuticals Inc | An in vivo library-versus-library selection of optimized protein-protein interactions |
EP1198586A1 (en) * | 1999-06-26 | 2002-04-24 | Odyssey Pharmaceuticals, Inc. | An in vivo library-versus-library selection of optimized protein-protein interactions |
EP2280066A3 (en) * | 2002-09-12 | 2011-05-11 | Health Protection Agency | Recombinant clostridium neurotoxin fragments |
US9006395B2 (en) | 2002-09-12 | 2015-04-14 | The Secretary Of State For Health | Recombinant toxin fragments |
EP2267024A1 (en) | 2005-06-03 | 2010-12-29 | Ares Trading S.A. | Production of recombinant il-18 binding protein |
US9505848B2 (en) | 2006-03-24 | 2016-11-29 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
JP2017046720A (en) * | 2006-03-24 | 2017-03-09 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Engineered heterodimeric protein domain |
US8871912B2 (en) | 2006-03-24 | 2014-10-28 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
AU2007229698B2 (en) * | 2006-03-24 | 2012-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
AU2007229698B9 (en) * | 2006-03-24 | 2012-11-08 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
WO2007110205A3 (en) * | 2006-03-24 | 2008-02-28 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
EP2662383A1 (en) | 2008-08-25 | 2013-11-13 | Amplimmune, Inc. | PD-I antagonists and methods for treating infectious disease |
US8653073B2 (en) | 2009-08-04 | 2014-02-18 | Les Laboratoires Servier | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them |
WO2011026132A2 (en) | 2009-08-31 | 2011-03-03 | 1/3Acamplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
US9957312B2 (en) | 2009-08-31 | 2018-05-01 | Medimmune, Llc | B7-H4 fusion proteins and methods of use thereof |
WO2011026122A2 (en) | 2009-08-31 | 2011-03-03 | Amplimmune, Inc. | B7-h4 fusion proteins and methods of use thereof |
US10781254B2 (en) | 2010-03-26 | 2020-09-22 | The Trustees Of Dartmouth College | VISTA regulatory T cell mediator protein, VISTA binding agents and use thereof |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
EP3202415A2 (en) | 2010-06-30 | 2017-08-09 | Compugen Ltd. | C1orf32 fused to the fc fragment for the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders |
WO2012001647A2 (en) | 2010-06-30 | 2012-01-05 | Compugen Ltd. | Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders |
WO2012035518A1 (en) | 2010-09-17 | 2012-03-22 | Compugen Ltd. | Compositions and methods for treatment of drug resistant multiple myeloma |
WO2012140627A1 (en) | 2011-04-15 | 2012-10-18 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
WO2013001517A1 (en) | 2011-06-30 | 2013-01-03 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
US10933115B2 (en) | 2012-06-22 | 2021-03-02 | The Trustees Of Dartmouth College | VISTA antagonist and methods of use |
US11752189B2 (en) | 2012-06-22 | 2023-09-12 | The Trustees Of Dartmouth College | Vista antagonist and methods of use |
US11180557B2 (en) | 2012-06-22 | 2021-11-23 | King's College London | Vista modulators for diagnosis and treatment of cancer |
US10633650B2 (en) | 2012-07-05 | 2020-04-28 | Genentech, Inc. | Expression and secretion system |
CN104428416A (en) * | 2012-07-05 | 2015-03-18 | 弗·哈夫曼-拉罗切有限公司 | Expression and secretion system |
US9803191B2 (en) | 2012-07-05 | 2017-10-31 | Genentech, Inc. | Expression and secretion system |
WO2014008391A1 (en) * | 2012-07-05 | 2014-01-09 | Genentech, Inc. | Expression and secretion system |
US11529416B2 (en) | 2012-09-07 | 2022-12-20 | Kings College London | Vista modulators for diagnosis and treatment of cancer |
WO2014124487A1 (en) | 2013-02-18 | 2014-08-21 | Vegenics Pty Limited | Ligand binding molecules and uses thereof |
EP3693381A1 (en) | 2013-02-18 | 2020-08-12 | Vegenics Pty Limited | Ligand binding molecules and uses thereof |
WO2014186798A1 (en) | 2013-05-17 | 2014-11-20 | Amplimmune, Inc. | Receptors for b7-h4 |
US11242392B2 (en) | 2013-12-24 | 2022-02-08 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
US11123426B2 (en) | 2014-06-11 | 2021-09-21 | The Trustees Of Dartmouth College | Use of vista agonists and antagonists to suppress or enhance humoral immunity |
WO2015190262A1 (en) * | 2014-06-13 | 2015-12-17 | 国立大学法人名古屋大学 | Tagged antibody |
JP2016002009A (en) * | 2014-06-13 | 2016-01-12 | 国立大学法人名古屋大学 | Tagged antibody |
WO2016030888A1 (en) | 2014-08-26 | 2016-03-03 | Compugen Ltd. | Polypeptides and uses thereof as a drug for treatment of autoimmune disorders |
US10370455B2 (en) | 2014-12-05 | 2019-08-06 | Immunext, Inc. | Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists |
US11009509B2 (en) | 2015-06-24 | 2021-05-18 | Janssen Pharmaceutica Nv | Anti-VISTA antibodies and fragments |
WO2017009712A1 (en) | 2015-07-13 | 2017-01-19 | Compugen Ltd. | Hide1 compositions and methods |
EP3971211A1 (en) | 2015-07-13 | 2022-03-23 | Compugen Ltd. | Hide1 compositions and methods |
US10899836B2 (en) | 2016-02-12 | 2021-01-26 | Janssen Pharmaceutica Nv | Method of identifying anti-VISTA antibodies |
US11603402B2 (en) | 2016-04-15 | 2023-03-14 | Immunext, Inc. | Anti-human vista antibodies and use thereof |
US11649283B2 (en) | 2016-04-15 | 2023-05-16 | Immunext, Inc. | Anti-human vista antibodies and use thereof |
US11525000B2 (en) | 2016-04-15 | 2022-12-13 | Immunext, Inc. | Anti-human VISTA antibodies and use thereof |
US11603403B2 (en) | 2016-04-15 | 2023-03-14 | Immunext, Inc. | Anti-human vista antibodies and use thereof |
US11649285B2 (en) | 2016-08-03 | 2023-05-16 | Bio-Techne Corporation | Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy |
WO2018107125A1 (en) * | 2016-12-09 | 2018-06-14 | Seattle Genetics, Inc. | Bivalent antibodies masked by coiled coils |
US11230610B2 (en) | 2016-12-09 | 2022-01-25 | Seagen Inc. | Bivalent antibodies masked by coiled coils |
US11787857B2 (en) | 2018-02-02 | 2023-10-17 | Bio-Techne Corporation | Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using |
WO2019217587A1 (en) * | 2018-05-08 | 2019-11-14 | Amgen Inc. | Bispecific antibodies with cleavable c-terminal charge-paired tags |
WO2022227066A1 (en) * | 2021-04-30 | 2022-11-03 | 深圳普瑞金生物药业有限公司 | METHOD FOR SCREENING αβ-TCR HETERODIMER MUTANTS |
Also Published As
Publication number | Publication date |
---|---|
EP1194539A2 (en) | 2002-04-10 |
CA2377513A1 (en) | 2001-01-04 |
WO2001000814A3 (en) | 2001-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1194539A2 (en) | Hetero-associating coiled-coil peptides and screening method therefor | |
US7625700B2 (en) | In vivo library-versus-library selection of optimized protein-protein interactions | |
Doolittle | The multiplicity of domains in proteins | |
CA2378871C (en) | Design of beta-sheet proteins with specific binding properties | |
AU2009251209B2 (en) | Isolating biological modulators from biodiverse gene fragment libraries | |
US6566057B1 (en) | Methods and compositions for peptide libraries displayed on light-emitting scaffolds | |
EP0781331B1 (en) | Improvements in or relating to binding proteins for recognition of dna | |
JP4493271B2 (en) | Combinatorial library of proteins having a skeleton structure of C-type lectin-like domain | |
US20080108789A1 (en) | DNA & protein binding miniature proteins | |
JP5385796B2 (en) | Method for producing active scFv antibodies and libraries thereof | |
EP1198586B1 (en) | An in vivo library-versus-library selection of optimized protein-protein interactions | |
Abedi et al. | Transcriptional transactivation by selected short random peptides attached to lexA-GFP fusion proteins | |
EP1470224A1 (en) | Molecular libraries | |
Zhang et al. | Affinity Selection of DNA-Binding Proteins Displayed on Bacteriophage λ | |
Woronowicz | Characterization of aPP derived miniature proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2377513 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000943898 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000943898 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000943898 Country of ref document: EP |